by In2Pharma | Feb 16, 2022 | News
The Netherlands Medicinal Product Quality Defects and Shortages on the Dutch Market should be reported through the “Meldpunt geneesmiddelentekorten en -defecten”. As of 01 January 2022, the Medicines Evaluation Board (MEB) and the Inspectorate (IGJ) have implemented...
